Palatin Technologies PTN
NASDAQ PTN
$12.02 -0.31 (-2.51%)
At close: Sep 10, 2026 · 4:00 PM EDT

Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024)

Palatin Technologies' (PTN) quarterly Total Non-Current Liabilities came in at $10.0 million in Q3 2024, down 29.17% on a YoY basis from $14.1 million in Q4 2023, and down 7.92% quarter-over-quarter from $10.9 million in Q2 2024.

Analysis

Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024) Analysis & Trends

Palatin Technologies (PTN) has reported Total Non-Current Liabilities for 10 consecutive years, with $10.0 million the latest figure, recorded in Q3 2024.

  • For the quarter ending Q3 2024, Total Non-Current Liabilities fell 29.17% year-over-year to $10.0 million; the trailing twelve-month figure through Sep 2024 stood at $10.0 million (down 29.17% YoY), and the FY2024 full-year result was $10.9 million, down 39.04% from the prior year.
  • Total Non-Current Liabilities fell to $10.0 million in Q3 2024 per PTN's latest filing, from $10.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $17.8 million in Q2 2023 and bottomed at $3.4 million in Q1 2020.
  • Historically, Total Non-Current Liabilities has averaged $11.7 million across 5 years, with a median of $11.9 million in 2022.
  • The sharpest annual moves came in 2020 and 2024: Total Non-Current Liabilities soared 489.5% in 2020, then plunged 39.04% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $8.1 million in 2020, then jumped by 82.41% to $14.8 million in 2021, then decreased by 19.51% to $11.9 million in 2022, then increased by 6.42% to $12.7 million in 2023, then fell by 21.08% to $10.0 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.0 million, $10.9 million, and $8.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 378.37 Mn
10 Palatin Technologies 46.98 Mn 46.98 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 9.99 Mn
Jun 30, 2024 10.85 Mn
Mar 31, 2024 8.80 Mn
Dec 31, 2023 12.66 Mn
Sep 30, 2023 14.11 Mn
Jun 30, 2023 17.81 Mn
Mar 31, 2023 12.24 Mn
Dec 31, 2022 11.90 Mn
Sep 30, 2022 16.45 Mn
Jun 30, 2022 16.94 Mn
Mar 31, 2022 12.74 Mn
Dec 31, 2021 14.78 Mn
Sep 30, 2021 10.60 Mn
Jun 30, 2021 11.41 Mn
Mar 31, 2021 11.02 Mn
Dec 31, 2020 8.11 Mn
Sep 30, 2020 13.56 Mn
Jun 30, 2020 4.88 Mn
Mar 31, 2020 3.36 Mn
Dec 31, 2019 1.37 Mn